Hydroxychloroquine in Individuals At Risk for Type 1 Diabetes

This clinical trial is testing a medication called hydroxychloroquine (HCQ) to assess safety and effectiveness in people at risk of developing T1D. The study is enrolling people with T1D autoantibodies confirmed by screening, to see if HCQ can prevent T1D developing.

HCQ is used as a treatment for malaria, lupus, and rheumatoid arthritis. It has also been used extensively for treatment of autoimmune disease in adults, children, and during pregnancy. This medication has not previously been studied as a treatment to prevent T1D.

If you’re interested in taking part, contact Leanne or Felicity at type1screen@mh.org.au, or call 03 9342 7063.